Full Text View
Tabular View
No Study Results Posted
Related Studies
Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females
This study is not yet open for participant recruitment.
Verified by Emory University, July 2009
First Received: December 22, 2008   Last Updated: August 11, 2009   History of Changes
Sponsors and Collaborators: Emory University
Merck
Information provided by: Emory University
ClinicalTrials.gov Identifier: NCT00813319
  Purpose

African American adolescent females seeking treatment for STIs are an underserved population at increased risk for HPV infection. While GARDASIL is an effective preventive vaccine, vaccination rates are low. Given the risk for HPV infection among this subgroup and the negative health effects associated with HPV, enhancing uptake of GARDASIL is necessary. To address this need, the proposed study is an exciting opportunity to build upon a relationship previously formed between Planned Parenthood of Georgia and Emory University Rollins School of Public Health. The goal of this project is to promote GARDASIL vaccination through the development of a new multi-component, culturally-appropriate, interactive DVD.

We propose to recruit 400 unmarried African American adolescent females, 13-18 years of age, from Planned Parenthood in Atlanta, Georgia. At Planned Parenthood, adolescents will be contacted and invited to participate in the proposed study. Eligible adolescents will be required to provide written assent/consent prior to participation. Adolescents who are eligible and willing to participate in the project will complete a short survey on a laptop computer. The survey is designed to assess adolescents' risk taking and preventive behaviors.

After they complete the survey, adolescents will be assigned at random to one of two groups. In one group, adolescents will watch a short (10 min), interactive DVD designed to promote HPV awareness and initial GARDASIL vaccination and receive a keepsake to help them remember to return to the clinic for their second and third vaccine doses. In the second group, adolescents will watch an equally short (10 min) DVD on healthy lifestyles and behaviors. All adolescents are eligible to receive the GARDASIL vaccine at Planned Parenthood as part of their routine standard of care.

With the help of clinic staff, participant medical records will be reviewed over a 6 month period to assess vaccination rates. Vaccination rates from adolescents who received the interactive HPV/GARDASIL awareness DVD will be compared to the group of adolescents who received the healthy lifestyles DVD. It is hypothesized that study participants receiving the interactive DVD intervention that promotes HPV awareness will have higher vaccination rates over time.


Condition Intervention Phase
Vaccination
Behavioral: Girls OnGuard
Phase III

Study Type: Interventional
Study Design: Prevention, Randomized, Open Label, Parallel Assignment, Efficacy Study
Official Title: Overcoming Barriers to Vaccination With GARDASIL in Underserved Girls and Adolescents

Further study details as provided by Emory University:

Primary Outcome Measures:
  • GARDASIL vaccination uptake and compliance with second and third doses [ Time Frame: measured at 6 months post-randomization ] [ Designated as safety issue: No ]

Estimated Enrollment: 400
Study Start Date: October 2009
Estimated Study Completion Date: November 2010
Estimated Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1 - Girls OnGuard/HPV awareness: Experimental
Adolescents will watch a short (10 min), interactive DVD designed to promote HPV awareness and initial GARDASIL vaccination and receive a keepsake to help them remember to return to the clinic for their second and third vaccine doses.
Behavioral: Girls OnGuard
Using the Information-Motivation-Behavioral Skills Model (IMB) as a framework, Girls OnGuard is an interactive,culturally-appropriate, computer-delivered program design to enhance initial uptake of GARDASIL by addressing three major components: (1) information about GARDASIL; (2) motivation to obtain GARDASIL vaccination; and (3) behavioral skills to enhance self-efficacy of obtaining GARDASIL vaccination.
2 - General health promotion: No Intervention
Adolescents will watch an equally short (10 min) DVD on healthy lifestyles and behaviors. HPV awareness and vaccination will not be addressed.

  Eligibility

Ages Eligible for Study:   13 Years to 18 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • African American
  • Female
  • Age 13-18 years
  • Seeking services at participating clinic
  • Ability to give written informed consent or assent

Exclusion Criteria:

  • Pregnant
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00813319

Contacts
Contact: Colleen C. Murray, DrPH, MPH 404-727-9872 ccritte@sph.emory.edu
Contact: Jessica M. Sales, PhD 404-727-6598 jmcderm@emory.edu

Locations
United States, Georgia
Planned Parenthood of Georgia
Atlanta, Georgia, United States, 30303
Sponsors and Collaborators
Emory University
Merck
Investigators
Principal Investigator: Ralph J. DiClemente, PhD Emory University Rollins School of Public Health
  More Information

No publications provided

Responsible Party: Emory University ( Ralph J. DiClemente, PhD )
Study ID Numbers: Merck - Emory UPN 08042902
Study First Received: December 22, 2008
Last Updated: August 11, 2009
ClinicalTrials.gov Identifier: NCT00813319     History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by Emory University:
GARDASIL
HPV
Vaccination

ClinicalTrials.gov processed this record on August 28, 2009